The Company is a real estate investment trust, or REIT, focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Note on this pick:
I bought in around $6.50. It was very obvious to me based on BMR's low amount of leverage, strong cash flows, and property portfolio that it was worth more than that.
As I write this, it sells at $16. I believe it is still slightly undervalued even at this price. Based on cash flows, equity interest in assets, and other factors, I'd value this company somewhere between $20 - $28, just based on a quick glance. I do, however, have some concerns about the locations of their properties (many being in bubble markets), so I'd probably stay on the conservative end of that.
I would not buy in at the current price. It's too expensive, in my view, when compared to other REITs. All the same, I plan on continuing my pick here on CAPS, especially since it pays out a sizable dividend. My strategy for CAPS on the REITs is buy-and-hold for life. If I see BMR tip over $25, I might consider ending my pick, but otherwise, I plan on keeping this pick forever.